Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.
Miyamoto M, Takano M, Iwaya K, Shinomiya N, Goto T, Kato M, Suzuki A, Aoyama T, Hitrata J, Nagaoka I, Tsuda H, Furuya K. Miyamoto M, et al. Among authors: furuya k. Br J Cancer. 2017 Mar 14;116(6):e2. doi: 10.1038/bjc.2016.371. Epub 2016 Nov 10. Br J Cancer. 2017. PMID: 27832666 Free PMC article. No abstract available.
Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
Soyama H, Miyamoto M, Takano M, Aoyama T, Matsuura H, Sakamoto T, Takasaki K, Kuwahara M, Kato K, Yoshikawa T, Iwahashi H, Tsuda H, Furuya K. Soyama H, et al. Among authors: furuya k. Med Oncol. 2017 Nov 22;34(12):201. doi: 10.1007/s12032-017-1058-3. Med Oncol. 2017. PMID: 29168038
Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers.
Yoshikawa T, Takano M, Miyamoto M, Yajima I, Shimizu Y, Aizawa Y, Suguchi Y, Moriiwa M, Aoyama T, Soyama H, Goto T, Hirata J, Suzuki A, Sasa H, Nagaoka I, Tsuda H, Furuya K. Yoshikawa T, et al. Among authors: furuya k. Cancer Chemother Pharmacol. 2017 Sep;80(3):555-561. doi: 10.1007/s00280-017-3395-5. Epub 2017 Jul 19. Cancer Chemother Pharmacol. 2017. PMID: 28726081
JAK2/STAT3 pathway as a therapeutic target in ovarian cancers.
Yoshikawa T, Miyamoto M, Aoyama T, Soyama H, Goto T, Hirata J, Suzuki A, Nagaoka I, Tsuda H, Furuya K, Takano M. Yoshikawa T, et al. Among authors: furuya k. Oncol Lett. 2018 Apr;15(4):5772-5780. doi: 10.3892/ol.2018.8028. Epub 2018 Feb 12. Oncol Lett. 2018. PMID: 29545902 Free PMC article.
1,117 results